Do we have all the facts to determine the impact of bacillus Calmette-Guérin therapy on bladder cancer?

Patients with intermediate to high risk non-muscle invasive bladder cancer (NMIBC) as defined by the European Organization of Research and Treatment of Cancer (EORTC) risk tables have an increased risk of recurrence and progression (1). Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is widely used to treat high risk NMIBC.